These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17173840)

  • 1. Pharmacovigilance study of a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form.
    Mahieu AC; Sisti AM; Joekes S; Manfredi MJ
    Allergol Immunopathol (Madr); 2006; 34(6):242-7. PubMed ID: 17173840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacovigilance study of a regional intravenous immunoglobulin].
    Sisti AM; Mahieu AC; Manfredi MJ
    Allergol Immunopathol (Madr); 2004; 32(6):326-33. PubMed ID: 15617659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency.
    Kallenberg CG
    Clin Exp Immunol; 2007 Dec; 150(3):437-41. PubMed ID: 17956584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin.
    Esmaeilzadeh H; Askarisarvestani A; Hosseini N; Samimi S; Shafiei A; Mahdaviani SA; Eslami N; Chavoshzadeh Z; Fallahi M; Khakbazanfard N; Shabestari MS; Aleyasin S; Nabavizadeh SH; Cheraghi T; Kalantari A; Ahmadiafshar A; Safari M; Eslamian MH; Molatefi R; Shirkani A; Heidarzadeh Arani M; Tavakol M; Bemanian MH; Arshi S; Nabavi M; Shokri S; Shahhosseini B; Mortazavi N; Nakhaei P; Nazari F; Fallahpour M; Ahanchian H; Moazzen N; Khoshkhui M; Motlagh AV; Aghamohammadi A; Abolhassani H; Yazdani R; Rezaei N
    Clin Immunol; 2021 Sep; 230():108826. PubMed ID: 34418548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.
    Nadeau JO; Bhibhatbhan A; McDougall D; Toth C
    Clin Neurol Neurosurg; 2010 Jul; 112(6):467-9. PubMed ID: 20227821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
    Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
    Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of adverse events when changing intravenous immunoglobulin preparations.
    Ameratunga R; Sinclair J; Kolbe J
    Clin Exp Immunol; 2004 Apr; 136(1):111-3. PubMed ID: 15030521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states.
    Tcheurekdjian H; Martin J; Kobayashi R; Wasserman R; Hostoffer R
    Allergy Asthma Proc; 2006; 27(6):532-6. PubMed ID: 17176791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion.
    Kato H; Hayashi M; Ohashi W; Yamaguchi T; Tanaka S; Kozono A; Gao S; Katai A; Niwa R; Matsuo T; Ishiyama K; Ando T; Ogawa M; Nakayama T
    Front Immunol; 2021; 12():740517. PubMed ID: 34603326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases.
    Dashti-Khavidaki S; Aghamohammadi A; Farshadi F; Movahedi M; Parvaneh N; Pouladi N; Moazzami K; Cheraghi T; Mahdaviani SA; Saghafi S; Heydari G; Abdollahzade S; Rezaei N
    J Investig Allergol Clin Immunol; 2009; 19(2):139-45. PubMed ID: 19476018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
    Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
    Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redimune NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions.
    Piguet D; Tosi C; Lüthi JM; Andresen I; Juge O;
    Clin Exp Immunol; 2008 Apr; 152(1):45-9. PubMed ID: 18241226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
    Günther G; Dreger B
    Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement.
    Ibis IBP; Erdur B; Erdem SB; Karaman S; Gulez N; Genel F
    Allergol Immunopathol (Madr); 2020; 48(6):738-744. PubMed ID: 32703652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases.
    Schiff RI; Williams LW; Nelson RP; Buckley RH; Burks W; Good RA
    J Clin Immunol; 1997 Jan; 17(1):21-8. PubMed ID: 9049782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
    Manlhiot C; Yeung RS; Chahal N; McCrindle BW
    Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of intravenous immunoglobulin (IVIG) therapy.
    Katz U; Achiron A; Sherer Y; Shoenfeld Y
    Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
    Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
    Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
    Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
    Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
    Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
    Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.